ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
4.030
-0.290 (-6.71%)
At close: Oct 23, 2026, 4:00 PM EDT
4.011
-0.019 (-0.46%)
After-hours: Oct 23, 2026, 7:43 PM EDT
ARS Pharmaceuticals Employees
As of June 30, 2026, ARS Pharmaceuticals had 200 total employees, including 195 full-time and 5 part-time employees. The number of employees increased by 33 or 19.76% compared to the same quarter last year. That makes ARS Pharmaceuticals the 26,899th largest employer in the world and 3,402nd in the United States.
Employees
200
Change (1Y)
33
Growth (1Y)
19.76%
Revenue / Employee
$584,635
Profits / Employee
-$1,077,160
Market Cap
400.77M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 200 | 33 | 19.76% | 195 | 5 |
| Mar 31, 2026 | 159 | -1 | -0.63% | 154 | 5 |
| Dec 31, 2025 | 163 | 3 | 1.88% | 158 | 5 |
| Sep 30, 2025 | 167 | 16 | 10.60% | 162 | 5 |
| Jun 30, 2025 | 167 | 139 | 496.43% | 162 | 5 |
| Dec 31, 2024 | 160 | 134 | 515.38% | 155 | 5 |
| Sep 30, 2024 | 151 | 124 | 459.26% | 146 | 5 |
| Jun 30, 2024 | 28 | -6 | -17.65% | 23 | 5 |
| Mar 31, 2024 | 26 | -5 | -16.13% | 24 | 2 |
| Dec 31, 2023 | 26 | 6 | 30.00% | 24 | 2 |
| Sep 30, 2023 | 27 | 16 | 145.45% | 24 | 3 |
| Jun 30, 2023 | 34 | 23 | 209.09% | 29 | 5 |
| Mar 31, 2023 | 31 | 22 | 244.44% | 27 | 4 |
| Dec 31, 2022 | 20 | 11 | 122.22% | 17 | 3 |
| Jun 30, 2022 | 11 | - | - | 9 | 2 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| ProKidney | 231 |
| Allogene Therapeutics | 152 |
| Assembly Biosciences | 73 |
| Prothena Corporation | 67 |
| AgomAb Therapeutics NV | 62 |
| TRex Bio | 60 |
| Tectonic Therapeutic | 60 |
SPRY News
- 4 weeks ago - Kaplan Fox Reminds ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors with Significant Losses to Seek a Leadership Role Before Deadline on October 5, 2026 - GlobeNewsWire
- 4 weeks ago - Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (SPRY) to Act Ahead of the Lead Plaintiff Deadline on October 5, 2026 - Newsfile Corp
- 5 weeks ago - Kaplan Fox Alerts ARS Pharmaceuticals Inc. (SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026 - Newsfile Corp
- 5 weeks ago - Kaplan Fox Urges ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery to Contact the Firm Before October 5, 2026 - Newsfile Corp
- 6 weeks ago - ARS Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 6 weeks ago - Kaplan Fox Encourages ARS Pharmaceuticals Inc. (SPRY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on October 5, 2026 - Newsfile Corp
- 6 weeks ago - ARS Pharmaceuticals price target lowered to $15 from $18 at Leerink - TheFly
- 7 weeks ago - ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire